This series of phase 3, randomised, double-blind, placebo-controlled clinical trials involved more than 25,000 individuals with overweight or obesity and has extensively demonstrated the efficacy of once-weekly subcutaneous semaglutide 2.4 mg in promoting weight loss [13, 38,39,40,41,42,43,44,45,46]
J Orthop Surg Res 18 , 386 (2023)
Eligibility typically requires household income below 200 to 400 percent of the federal poverty level, depending on the specific program and medication
Unfortunately, doctors dont usually test for insulin resistance, even if you suspect it, because no single test can detect it
However, you should continue to take Rybelsus as directed (on an empty stomach, at least 30 minutes before other oral medicines)